Clinical Trial Update: A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 study comparing DB-1303/BNT323 with T-DM1 in HER2-positive breast cancer is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DB-1303/BNT323
• T-DM1 (ado-trastuzumab emtansine)

Snippet

Sponsor: DualityBio Inc. | Conditions: HER2-positive Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING